文献速递系统性红斑狼疮其他结缔组织病

系统性红斑狼疮患者自身免疫性多内分泌综合征的病例对照研究

A case-control study on autoimmune polyendocrine syndromes in patients with systemic lupus erythematosus.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该病例对照研究分析了2021至2023年间转诊至本中心的417例系统性红斑狼疮(SLE)患者,其中47例(11%)符合自身免疫性多内分泌综合征(APS)诊断,以APS 3型为主(45例);与185例无APS的SLE对照相比,两组临床及血清学特征无显著差异,APS阳性患者中位SLICC损伤指数(SDI)略高但未伴疾病活动度增加。

要点

  • 417例SLE患者中47例(11%)诊断APS,45例为APS 3型、2例为APS 4型,无APS 1型或2型。
  • APS阳性与阴性SLE患者临床及血清学特征无显著差异。
  • 末次评估时两组约80%患者处于临床缓解,约半数仍使用激素治疗。

核心结论

  • SLE患者中APS患病率(11%)显著高于一般人群(0.005%),证实自身免疫性甲状腺炎与SLE相关。
  • APS阳性的SLE患者似乎并无更具侵袭性的疾病或更多并发症。

研究设计与样本

  • 病例对照研究,分析2021至2023年间转诊至本中心的417例SLE患者(符合SLICC 2012和/或EULAR/ACR 2019标准)的临床病历。
  • 采用ORPHA定义识别APS病例;随机纳入185例无APS的SLE患者作为对照。
  • 收集人口学、临床及血清学数据。

主要发现

  • 417例SLE患者中47例(11%)存在可诊断APS的其他腺体自身免疫病:39例桥本甲状腺炎、6例Graves病、3例1型糖尿病。
  • 45例为APS 3型,2例为APS 4型;无患者诊断为APS 1型或2型。
  • APS阳性与阴性患者临床或血清学特征无显著差异。
  • 末次评估时两组约80%患者处于临床缓解,约半数患者仍接受激素治疗。
  • APS阳性患者中位SLICC损伤指数(SDI)略高,但未伴疾病活动度增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to investigate the prevalence of autoimmune polyendocrine syndromes in patients with SLE and to assess whether autoimmune polyendocrine syndromes predict higher disease activity or worse outcomes. METHODS: The clinical charts of 417 SLE patients (meeting SLICC 2012 and/or EULAR/ACR 2019 criteria)( referred to our centre between 2021 and 2023 were analysed. Autoimmune polyendocrine syndrome cases were identified using ORPHA definitions; 185 autoimmune polyendocrine syndrome-free SLE patients, randomly enrolled, served as controls. Demographic, clinical and serological data were collected. RESULTS: Forty-seven of 417 (11%) SLE patients had another autoimmune disease affecting the glands that allowed the diagnosis of autoimmune polyendocrine syndrome: 39 were diagnosed with Hashimoto thyroiditis, 6 with Graves' disease, and 3 with type 1 diabetes mellitus. Forty-five were affected by autoimmune polyendocrine syndrome type 3, and 2 by autoimmune polyendocrine syndrome type 4; no patients were diagnosed with autoimmune polyendocrine syndrome types 1 or 2. A comparison between the autoimmune polyendocrine syndrome-positive and -negative patients revealed no significant differences in clinical or serological features. At the last evaluation, ∼80% of both groups of patients were in clinical remission, and approximately half of the patients remained on steroid therapy. Autoimmune polyendocrine syndrome-positive patients had a slightly higher median SLICC Damage Index (SDI), although this was not associated with increased disease activity. CONCLUSION: The prevalence of autoimmune polyendocrine syndrome among SLE patients is significantly higher than in the general population (11% vs 0.005%), confirming the association between autoimmune thyroiditis and SLE. However, autoimmune polyendocrine syndrome-positive patients do not appear to have a more aggressive disease or develop more complications.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Piovani E, Gozzoli GI, Della Pina SEL, et al. A case-control study on autoimmune polyendocrine syndromes in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 40495344. doi:10.1093/rheumatology/keaf320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。